Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist

Neuropharmacology

Volumn 95, Issue , 2015, Pages 121-129

  Iderberg, Hanna ^a   Maslava, Natallia ^a   Thompson, Analisa D ^b   Bubser, Michael ^b   Niswender, Colleen M ^b   Hopkins, Corey R ^b,c   Lindsley, Craig W ^b,c   Conn, P Jeffrey ^b   Jones, Carrie K ^b   Cenci, M Angela ^a  

^a LUND UNIVERSITY   (Sweden)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Dopamine; Dyskinesias; Glutamate; Metabotropic receptor; Movement disorders; Parkinson's disease; Plasticity

Indexed keywords

HALOPERIDOL; LEVODOPA; LSP 1 2111; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR AGONIST; N (3 CHLOROPHENYL)PICOLINAMIDE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR AFFECTING AGENT; AMINOBUTYRIC ACID DERIVATIVE; ANTIPARKINSON AGENT; LSP1 2111; METABOTROPIC RECEPTOR; N-(3-CHLOROPHENYL)PICOLINAMIDE; OXIDOPAMINE; PHOSPHINIC ACID DERIVATIVE; PICOLINIC ACID DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; DRUG RESPONSE; DYSKINESIA; FEMALE; HALOPERIDOL-INDUCED CATALEPSY; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; AGONISTS; ANIMAL; CATALEPSY; COMPARATIVE STUDY; DYSKINESIA, DRUG-INDUCED; METABOLISM; PARKINSONIAN DISORDERS; RANDOMIZATION; SPRAGUE DAWLEY RAT;

AMINOBUTYRATES; ANIMALS; ANTIPARKINSON AGENTS; CATALEPSY; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID AGENTS; HALOPERIDOL; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHOSPHINIC ACIDS; PICOLINIC ACIDS; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84925389242     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.02.023     Document Type: Article

References (54)

1. Acher, F., Selvam, C., Triballeau, N., Pin, J., Bertrand, H., 2007. Hypophosphorous acid derivatives and their therapeutical applications. In: US Patent Application, vol. WO2007052169.
2. F.C. Acher, F.J. Tellier, R. Azerad, I.N. Brabet, L. Fagni, and J.P. Pin Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes J. Med. Chem. 40 1997 3119 3129
3. R.L. Albin, A.B. Young, and J.B. Penney The functional anatomy of basal ganglia disorders Trends Neurosci. 12 1989 366 375
4. P.J. Austin, M.J. Betts, M. Broadstock, M.J. O'Neill, S.N. Mitchell, and S. Duty Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease Br. J. Pharmacol. 160 2010 1741 1753
5. V. Bagetta, C. Sgobio, V. Pendolino, G. Del Papa, A. Tozzi, V. Ghiglieri, C. Giampa, E. Zianni, F. Gardoni, P. Calabresi, and B. Picconi Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease J. Neurosci. 32 2012 17921 17931
6. H.S. Bateup, E. Santini, W. Shen, S. Birnbaum, E. Valjent, D.J. Surmeier, G. Fisone, E.J. Nestler, and P. Greengard Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors Proc. Natl. Acad. Sci. U. S. A. 107 2010 14845 14850
7. K.E. Bennouar, M.A. Uberti, C. Melon, M.D. Bacolod, H.N. Jimenez, M. Cajina, L. Kerkerian-Le Goff, D. Doller, and P. Gubellini Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia Neuropharmacology 66 2013 158 169
8. C. Beurrier, S. Lopez, D. Revy, C. Selvam, C. Goudet, M. Lherondel, P. Gubellini, L. Kerkerian-LeGoff, F. Acher, J.P. Pin, and M. Amalric Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism FASEB J. 23 2009 3619 3628
9. J. Bogenpohl, A. Galvan, X. Hu, T. Wichmann, and Y. Smith Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex Neuropharmacology 66 2013 242 252
10. S.R. Bradley, D.G. Standaert, K.J. Rhodes, H.D. Rees, C.M. Testa, A.I. Levey, and P.J. Conn Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia J. Comp. Neurol. 407 1999 33 46
11. L.S. Breger, S.B. Dunnett, and E.L. Lane Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat Neurobiol. Dis. 50 2013 142 150
12. J.M. Brotchie Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease Mov. Disord. 13 1998 871 876
13. M. Cajina, M. Nattini, D. Song, G. Smagin, E.B. Jorgensen, G. Chandrasena, C. Bundgaard, D.B. Toft, X. Huang, F. Acher, and D. Doller Qualification of LSP1-2111 as a brain penetrant group III metabotropic glutamate receptor orthosteric agonist ACS Med. Chem. Lett. 5 2014 119 123
14. M.A. Cenci Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia Trends Neurosci. 30 2007 236 243
15. M.A. Cenci Presynaptic mechanisms of L-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications Front. Neurol. 5 2014
16. M.A. Cenci, and C. Konradi Maladaptive striatal plasticity in L-DOPA-induced dyskinesia Prog. Brain Res. 183 2010 209 233
17. M.A. Cenci, C.S. Lee, and A. Bjorklund L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10 1998 2694 2706
18. M.A. Cenci, K.E. Ohlin, and P. Odin Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease CNS Neurol. Disord. Drug Targets 10 2011 670 684
19. A. Cerasa, A. Fasano, F. Morgante, G. Koch, and A. Quattrone Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology Front. Neurol. 5 2014 49
20. P.J. Conn, G. Battaglia, M.J. Marino, and F. Nicoletti Metabotropic glutamate receptors in the basal ganglia motor circuit Nat. Rev. Neurosci. 6 2005 787 798
21. S. Darmopil, A.B. Martin, I.R. De Diego, S. Ares, and R. Moratalla Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation Biol. Psychiatry 66 2009 603 613
22. M.A. Delfino, A.V. Stefano, J.E. Ferrario, I.R. Taravini, M.G. Murer, and O.S. Gershanik Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias Behav. Brain Res. 152 2004 297 306
23. C. Finlay, and S. Duty Therapeutic potential of targeting glutamate receptors in Parkinson's disease J. Neural Transm. 121 2014 861 880
24. V. Francardo, A. Recchia, N. Popovic, D. Andersson, H. Nissbrandt, and M.A. Cenci Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease Neurobiol. Dis. 42 2011 327 340
25. M. Heiman, A. Heilbut, V. Francardo, R. Kulicke, R.J. Fenster, E.D. Kolaczyk, J.P. Mesirov, D.J. Surmeier, M.A. Cenci, and P. Greengard Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia Proc. Natl. Acad. Sci. U. S. A. 111 2014 4578 4583
26. R.A. Hodgson, R. Bertorelli, G.B. Varty, J.E. Lachowicz, A. Forlani, S. Fredduzzi, M.E. Cohen-Williams, G.A. Higgins, F. Impagnatiello, E. Nicolussi, L.E. Parra, C. Foster, Y. Zhai, B.R. Neustadt, A.W. Stamford, E.M. Parker, A. Reggiani, and J.C. Hunter Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e ][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression J. Pharmacol. Exp. Ther. 330 2009 294 303
27. H. Iderberg, V. Francardo, and E.Y. Pioli Animal models of L-DOPA-induced dyskinesia: an update on the current options Neuroscience 211 2012 13 27
28. H. Iderberg, D. Rylander, Z. Bimpisidis, and M.A. Cenci Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action Exp. Neurol. 250 2013 116 124
29. K.A. Johnson, P.J. Conn, and C.M. Niswender Glutamate receptors as therapeutic targets for Parkinson's disease CNS Neurol. Disord. Drug Targets 8 2009 475 491
30. C.K. Jones, M. Bubser, A.D. Thompson, J.W. Dickerson, N. Turle-Lorenzo, M. Amalric, A.L. Blobaum, T.M. Bridges, R.D. Morrison, S. Jadhav, D.W. Engers, K. Italiano, J. Bode, J.S. Daniels, C.W. Lindsley, C.R. Hopkins, P.J. Conn, and C.M. Niswender The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease J. Pharmacol. Exp. Ther. 340 2012 404 421
31. E. Le Poul, C. Bolea, F. Girard, S. Poli, D. Charvin, B. Campo, J. Bortoli, A. Bessif, B. Luo, A.J. Koser, L.M. Hodge, K.M. Smith, A.G. DiLella, N. Liverton, F. Hess, S.E. Browne, and I.J. Reynolds A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease J. Pharmacol. Exp. Ther. 343 2012 167 177
32. H.S. Lindgren, D.R. Andersson, S. Lagerkvist, H. Nissbrandt, and M.A. Cenci L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J. Neurochem. 112 2010 1465 1476
33. S. Lopez, A. Bonito-Oliva, S. Pallottino, F. Acher, and G. Fisone Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease J. Parkinson's Dis. 1 2011 339 346
34. S. Lopez, N. Turle-Lorenzo, F. Acher, E. De Leonibus, A. Mele, and M. Amalric Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease J. Neurosci. 27 2007 6701 6711
35. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur. J. Neurosci. 15 2002 120 132
36. M. Lundblad, E. Vaudano, and M.A. Cenci Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia J. Neurochem. 84 2003 1398 1410
37. M.J. Marino, D.L. Williams Jr., J.A. O'Brien, O. Valenti, T.P. McDonald, M.K. Clements, R. Wang, A.G. DiLella, J.F. Hess, G.G. Kinney, and P.J. Conn Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment Proc. Natl. Acad. Sci. U. S. A. 100 2003 13668 13673
38. M. Morelli, A.R. Carta, and P. Jenner Adenosine A2A receptors and Parkinson's disease Handb. Exp. Pharmacol. 2009 589 615
39. C.M. Niswender, K.A. Johnson, C.D. Weaver, C.K. Jones, Z. Xiang, Q. Luo, A.L. Rodriguez, J.E. Marlo, T. de Paulis, A.D. Thompson, E.L. Days, T. Nalywajko, C.A. Austin, M.B. Williams, J.E. Ayala, R. Williams, C.W. Lindsley, and P.J. Conn Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4 Mol. Pharmacol. 74 2008 1345 1358
40. M. Olsson, G. Nikkhah, C. Bentlage, and A. Bjorklund Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test J. Neurosci. 15 1995 3863 3875
41. J. Palfreman Who dropped the ball on L-DOPA? A patient's lament J. Parkinson's Dis. 4 2014 313 316
42. G. Paxinos The Rat Nervous System third ed. 2004 Elsevier Academic Press
43. O. Rascol, S. Fox, F. Gasparini, C. Kenney, T. Di Paolo, and B. Gomez-Mancilla Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias Park. Relat. Disord. 20 2014 947 956
44. D. Rylander, H. Iderberg, Q. Li, A. Dekundy, J. Zhang, H. Li, R. Baishen, W. Danysz, E. Bezard, and M.A. Cenci A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys Neurobiol. Dis. 39 2010 352 361
45. D. Rylander, A. Recchia, F. Mela, A. Dekundy, W. Danysz, and M.A. Cenci Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling J. Pharmacol. Exp. Ther. 330 2009 227 235
46. D. Salat, and E. Tolosa Levodopa in the treatment of Parkinson's disease: current status and new developments J. Parkinson's Dis. 3 2013 255 269
47. S.A. Schneider, and J.A. Obeso Clinical and pathological features of Parkinson's disease Curr. Top. Behav. Neurosci. 2014
48. V. Sgambato-Faure, and M.A. Cenci Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease Prog. Neurobiol. 96 2012 69 86
49. O. Valenti, M.J. Marino, M. Wittmann, E. Lis, A.G. DiLella, G.G. Kinney, and P.J. Conn Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse J. Neurosci. 23 2003 7218 7226
50. C. Warren Olanow, K. Kieburtz, O. Rascol, W. Poewe, A.H. Schapira, M. Emre, H. Nissinen, M. Leinonen, F. Stocchi, and Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease I Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease Mov. Disord. 28 2013 1064 1071
51. J.E. Westin, L. Vercammen, E.M. Strome, C. Konradi, and M.A. Cenci Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors Biol. Psychiatry 62 2007 800 810
52. M.A. Wigmore, and M.G. Lacey Metabotropic glutamate receptors depress glutamate-mediated synaptic input to rat midbrain dopamine neurones in vitro Br. J. Pharmacol. 123 1998 667 674
53. C. Winkler, D. Kirik, A. Bjorklund, and M.A. Cenci L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 10 2002 165 186
54. M. Wittmann, M.J. Marino, S.R. Bradley, and P.J. Conn Activation of group III mGluRs inhibits GABAergic and glutamatergic transmission in the substantia nigra pars reticulata J. Neurophysiol. 85 2001 1960 1968